CGP 22979A, a renal vasodilator with natriuretic properties

Area of Science:

• Pharmacology
• Nephrology
• Cardiovascular Research

Background:

• Renal vasodilation presents a potential strategy for novel antihypertensive treatments.
• The prodrug approach was utilized to develop a compound with preferential renal vasodilatory effects.

Purpose of the Study:

• To synthesize and evaluate CGP 22979A, a novel prodrug derivative of CGP 18137A, for its potential as a selective renal vasodilator.
• To investigate the hemodynamic and functional effects of CGP 22979A on the renal vasculature and systemic circulation.

Main Methods:

• CGP 22979A was synthesized by conjugating an N-acetyl-gamma-glutamyl residue to CGP 18137A.
• In vitro assays assessed activity on isolated mesenteric arteries.
• In vivo studies in anesthetized and conscious rats evaluated effects on renal blood flow, blood pressure, glomerular filtration rate, and sodium excretion.

Main Results:

• CGP 22979A demonstrated selective renal vasodilation in rats, increasing renal blood flow by up to 31% without affecting systemic blood pressure.
• A dose of 4.0 mg/kg significantly reduced renal vascular resistance by 25% but did not impact other systemic vascular beds.
• Higher doses increased glomerular filtration rate by up to 42% and enhanced sodium excretion by 200% in conscious rats.

Conclusions:

• CGP 22979A acts as a potent and selective renal vasodilator in rats, primarily affecting afferent arterioles.
• The compound's ability to increase renal blood flow and glomerular filtration rate, coupled with its lack of systemic hypotensive effects, suggests potential as a therapeutic agent for hypertension.
• CGP 22979A may serve as a valuable pharmacological tool for further research into the antihypertensive benefits of renal vasodilation.